| ²é¿´: 3028 | »Ø¸´: 4 | |||||
| µ±Ç°Ö»ÏÔʾÂú×ãÖ¸¶¨Ìõ¼þµÄ»ØÌû£¬µã»÷ÕâÀï²é¿´±¾»°ÌâµÄËùÓлØÌû | |||||
niebiao2008ÖÁ×ðľ³æ (ÖøÃûдÊÖ)
study
|
[½»Á÷]
CMC²ÄÁÏ׫дģ°å ÒÑÓÐ4È˲ÎÓë
|
||||
|
CMC²ÄÁÏ׫дģ°å Chemistry, Manufacturing and Controls S DRUG SUBSTANCEÔÁÏÒ© S.1 General Information»ù±¾ÐÅÏ¢ S.1.1 NomenclatureÒ©Æ·Ãû³Æ ² International Nonproprietary NameͨÓÃÃû ² Chemical name»¯Ñ§Ãû ² Chemical Abstracts Service Registry Number CASºÅ S.1.2 Structure½á¹¹ ² structural formula (stereochemistry)½á¹¹Ê½£¨Á¢Ìå¹¹ÐÍ£© ² molecular formula·Ö×Óʽ ² molecular weight·Ö×ÓÁ¿ ² amino acid sequence°±»ùËáÐòÁÐ S.1.3 General PropertiesÀí»¯ÐÔÖÊ£¨ÁÐ±í£© ² general description (appearance, color, physical state)ÐÔ×´£¨Íâ¹Û¡¢ÑÕÉ«¡¢Îï̬£© ² melting or boiling pointsÈÛµã»ò·Ðµã ² optical rotation±ÈÐý¶È ² solubility profileÈܽâÐÔ ² solution pHÈÜÒºpH ² partition coefficients·ÖÅäϵÊý ² dissociation constants½âÀë³£Êý ² physical form (polymorph, solvate, hydrate)ÎïÖÊÐÎʽ£¨¶à¾§ÐÍÎï¡¢ÈܼÁ»¯ÎˮºÏÎ ² hygroscopicityÒýʪÐÔ ² particle size¿ÅÁ£¶È S.2 ManufactureÉú²úÐÅÏ¢ S.2.1 ManufacturersÉú²úÉÌ ² nameÃû³Æ£»addressµØÖ·£»responsibilityÖ°Ôð£»postcodeÓʱࣻtelephone numberµç»°ºÅÂ룻fax number´«ÕæºÅÂ룻contractorÁªÏµÈË£»e-mailµç×ÓÓÊÏä S.2.2 Description of Manufacturing Process and Process ControlsÉú²ú¹¤Òպ͹¤ÒÕ¿ØÖÆ S.2.2.1 Flow DiagramºÏ³É·Ïßͼ/¹¤ÒÕÁ÷³Ìͼ S.2.2.2 Description of the Manufacturing Process and Process Controls¹¤ÒÕÃèÊö S.2.2.3 Reprocessing, Reworking, Recycling, Regeneration, and Other Operations·µ¹¤ S.2.3 Control of MaterialsÎïÁÏ¿ØÖÆ S.2.3.1 Starting MaterialsÆðʼÔÁÏ S.2.3.2 Reagents, Solvents, and Auxiliary MaterialsÊÔ¼Á¡¢ÈܼÁ¡¢¸¨Öú²ÄÁÏ S.2.3.3 DiluentsÏ¡ÊͼÁ S.2.4 Controls of Critical Steps and Intermediates¹Ø¼ü²½ÖèºÍÖмäÌåµÄ¿ØÖÆ S.2.4.1 Critical Steps and Critical Operating Parameters¹Ø¼ü²½Öè¼°¹Ø¼ü¹¤ÒÕ²ÎÊý S.2.4.2 Controls of IntermediatesÖмäÌå¿ØÖÆ S.2.5 Process Validation and/or Evaluation¹¤ÒÕÑéÖ¤ºÍÆÀ¼Û S.2.6 Manufacturing Process DevelopmentÉú²ú¹¤ÒյĿª·¢ ² ºÏ³É·ÏßµÄÑ¡ÔñºÍÓÅ»¯ ² ¹Ø¼ü¹¤ÒÕ²ÎÊýµÄÈ·¶¨ ² ¹¤ÒÕ·Å´óÑо¿ S.3 CharacterizationÌØÐÔ¼ø¶¨ S.3.1 Elucidation of Structure and Other Characteristics½á¹¹ºÍÀí»¯ÐÔÖÊ S.3.1.1 Elucidation of Structure½á¹¹È·Ö¤ ² elemental analysisÔªËØ·ÖÎö£»MSÖÊÆ×£»NMR spectroscopyºË´ÅͼÆ×£»UV spectroscopy×ÏÍâ¹âÆ×£»IR spectroscopyºìÍâ¹âÆ× S.3.1.2 Physicochemical CharacterizationÀí»¯ÐÔÖÊ ² X-ray diffraction (single crystal or powder)XÉäÏßÑÜÉ䣨µ¥¾§»ò·ÛÄ©£©£»particle size analysis¿ÅÁ£¶È·ÖÎö£»DSCʾ²îɨÃèÁ¿ÈÈ·¨£»FTIR¸µÁ¢Ò¶×ª»»ºìÍâÏß¹âÆ×£»TGAÈÈÖØ·ÖÎö S.3.1.3 Biological and Other Relevant CharacteristicsÆäËûÐÔÖÊ S.3.2 ImpuritiesÔÓÖÊ ² nameÔÓÖÊÃû³Æ£»structureÔÓÖʽṹ£»¿ØÖÆÏÞ¶È£»ÔÓÖÊÀ´Ô´£»ÊÇ·ñ¶¨ÈëÖÊÁ¿±ê×¼ S.4 Control of Drug SubstanceÔÁÏÒ©µÄÖÊÁ¿¿ØÖÆ S.4.1 SpecificationÖÊÁ¿±ê×¼£¨ÁÐ±í£© ² tests¼ì²âÏîÄ¿£ºappearanceÍâ¹Û£»identification tests¼ø±ð£»melting rangeÈ۳̣»residue on ignition³ãׯ²ÐÔü£»heavy metalsÖØ½ðÊô£»specified impuritiesÓйØÎïÖÊ£»unspecified impurities·ÇÌØ¶¨ÔÓÖÊ£»total organic impurities×ÜÔÓ£»residual solvent²ÐÁôÈܼÁ£»particle size distributionÁ£¾¶·Ö²¼£¨D10¡¢D50¡¢D90£©£»water contentË®·Ö£»¶ÔÓ³Òì¹¹Ì壻º¬Á¿²â¶¨ ² release and shelf-life acceptance criteria·ÅÐбê×¼ÏÞ¶È/»õ¼ÜÆÚ±ê×¼ÏÞ¶È£ºNMT (not more than)²»¸ßÓÚ£»NLT (not less than)²»µÍÓÚ ² analytical procedure·½·¨£ºHPLC£»GC S.4.2 Analytical Procedures·ÖÎö·½·¨£¨ÆóÒµ·½·¨£© ² º¬Á¿¼ì²â·½·¨ ² ÓйØÎïÖʼì²â·½·¨ ² ¶ÔÓ¦Òì¹¹Ìå¼ì²â·½·¨ ² ²ÐÁôÈܼÁ¼ì²â·½·¨ S.4.3 Validation of Analytical Procedures·ÖÎö·½·¨µÄÑéÖ¤ ² רÊôÐÔ£»¼ì²âÏÞ£»¶¨Á¿ÏÞ£»ÏßÐԺͷ¶Î§£»¾«Ãܶȣ»×¼È·¶È£»ÄÍÓÃÐÔ S.4.4 Batch AnalysesÅú¼ìÑ鱨¸æ Åú´Î1£»Åú´Î2£»Åú´Î3 S.4.5 Justification of SpecificationÖÊÁ¿±ê×¼ÖÆ¶¨ÒÀ¾Ý S.5 Reference Standards or Materials¶ÔÕÕÆ· S.6 Container Closure System°ü×°²ÄÁϺÍÈÝÆ÷ S.7 StabilityÎȶ¨ÐÔ S.7.1 Stability Summary and ConclusionsÎȶ¨ÐÔ×ܽá S.7.2 Postapproval Stability Protocol and Stability CommitmentÉÏÊкóÎȶ¨ÐÔ·½°¸ºÍ³Ðŵ S.7.3 Stability DataÎȶ¨ÐÔÊý¾Ý P DRUG PRODUCTÖÆ¼Á P.1 Description and Composition of the Drug Product¼ÁÐͼ°²úÆ·×é³É ² component³É·Ö£»amountÓÃÁ¿£»overage¹ýÁ¿£»function×÷Óã»quality standardÖÊÁ¿±ê×¼ P.2 Pharmaceutical Development²úÆ·¿ª·¢ P.2.1 Components of the Drug Product´¦·½×é³É P.2.1.1 Drug SubstanceÔÁÏÒ© ² the compatibility of the drug substance with the excipientsÔÁÏÒ©Ó븨ÁϵÄÏàÈÝÐÔ ² key physicochemical characteristicsÖØÒªÀí»¯ÐÔÖÊ P.2.1.2 Excipients¸¨ÁÏ ² the choice of excipients¸¨ÁÏÖÖÀàµÄÑ¡Ôñ ² concentration of excipients¸¨ÁϵÄÓÃÁ¿ P.2.2 Drug ProductÖÆ¼ÁÑо¿ P.2.2.1 Formulation Development´¦·½¿ª·¢¹ý³Ì P.2.2.2 Overages¹ýÁ¿ P.2.2.3 Physicochemical and Biological PropertiesÀí»¯ÌØÐÔºÍÉúÎïÑ§ÌØÐÔ P.2.3 Manufacturing Process DevelopmentÉú²ú¹¤ÒյĿª·¢ P.2.4 Container Closure System°ü×°²ÄÁϺÍÈÝÆ÷ ² the suitability of the container closure system°ü×°²ÄÁϺÍÈÝÆ÷µÄºÏÊÊÐÔ P.2.5 Microbiological Attributes΢ÉúÎïÐÔÖÊ P.2.6 CompatibilityÏàÈÝÐÔ ² the compatibility of the drug product with reconstitution diluents or dosage devices P.3 ManufactureÉú²úÐÅÏ¢ P.3.1 ManufacturersÉú²úÉÌ ² nameÃû³Æ£»addressµØÖ·£»responsibilityÖ°Ôð£»contractorÁªÏµÈË P.3.2 Batch FormulaÅú´¦·½ ² component³É·Ö£»amountÓÃÁ¿£»overage¹ýÁ¿£»function×÷Óã»quality standardÖÊÁ¿±ê×¼ P.3.3 Description of Manufacturing Process and Process ControlsÉú²ú¹¤Òպ͹¤ÒÕ¿ØÖÆ P.3.2.1 Flow Diagram¹¤ÒÕÁ÷³Ìͼ P.3.2.2 Description of the Manufacturing Process and Process Controls¹¤ÒÕÃèÊö P.3.4 Controls of Critical Steps and Intermediates¹Ø¼ü²½ÖèºÍÖмäÌåµÄ¿ØÖÆ P.3.5 Process Validation and/or Evaluation¹¤ÒÕÑéÖ¤ºÍÆÀ¼Û ² ¹¤ÒÕÑéÖ¤·½°¸ ² ¹¤ÒÕÑéÖ¤±¨¸æ P.4 Control of Excipients¸¨ÁϵĿØÖÆ P.4.1 SpecificationsÖÊÁ¿±ê×¼ P.4.2 Analytical Procedures·ÖÎö·½·¨ P.4.3 Validation of Analytical Procedures·ÖÎö·½·¨µÄÑéÖ¤ P.4.4 Justification of SpecificationsÖÊÁ¿±ê×¼ÖÆ¶¨ÒÀ¾Ý P.4.5 Excipients of Human or Animal OriginÈËÔ´»ò¶¯ÎïÔ´¸¨ÁÏ P.4.6 Novel Excipientsи¨ÁÏ P. 5 Control of Drug ProductÖÆ¼ÁµÄÖÊÁ¿¿ØÖÆ P.5.1 SpecificationsÖÊÁ¿±ê×¼ ² tests¼ì²éÏîÄ¿£ºdescriptionÐÔ×´£»identification test¼ø±ð£»core weightÖØÁ¿²îÒ죻dissolutionÈܳö¶È£»water contentË®·Ö£»specified degradation productsÓйØÎïÖÊ£»unspecified degradation product·ÇÌØ¶¨ÔÓÖÊ£»total degradation products×ÜÔÓ£»residual solvent²ÐÁôÈܼÁ£»Î¢ÉúÎïÏÞ¶È£»º¬Á¿²â¶¨ ² release and shelf-life acceptance criteria·ÅÐбê×¼ÏÞ¶È/»õ¼ÜÆÚ±ê×¼ÏÞ¶È£ºNMT (not more than)²»¸ßÓÚ£»NLT (not less than)²»µÍÓÚ ² analytical procedure·½·¨£ºHPLC£»GC P.5.2 Analytical Procedures·ÖÎö·½·¨ ² º¬Á¿²â¶¨·½·¨ ² ÓйØÎïÖʼì²â·½·¨ ² Èܳö¶È²â¶¨·½·¨ ² ÖØÁ¿²îÒì²â¶¨·½·¨ ² ΢ÉúÎïÏ޶ȼì²é·½·¨ P.5.3 Validation of Analytical Procedures·ÖÎö·½·¨µÄÑéÖ¤ ² ²¨³¤Ñ¡Ôñ£»×¨ÊôÐÔ£»ÏµÍ³ÊÊÓÃÐÔ£»¼ì²âÏÞ£»ÈÜÒºÎȶ¨ÐÔ£»ÄÍÓÃÐÔ£»ÏßÐÔÓ뷶Χ£»¶¨Á¿ÏÞ£»»ØÊÕÂÊ£»¾«Ãܶȣ»×¼È·¶È P.5.4 Batch AnalysesÅú¼ìÑ鱨¸æ Åú´Î1£»Åú´Î2£»Åú´Î3 P.5.5 Characterization of ImpuritiesÔÓÖÊ·ÖÎö ² nameÔÓÖÊÃû³Æ£»structureÔÓÖʽṹ£»¿ØÖÆÏÞ¶È£»ÔÓÖÊÀ´Ô´£»ÊÇ·ñ¶¨ÈëÖÊÁ¿±ê×¼ P.5.6 Justification of SpecificationsÖÊÁ¿±ê×¼ÖÆ¶¨ÒÀ¾Ý P.6 Reference Standards or Materials¶ÔÕÕÆ· P.7 Container Closure System°ü×°²ÄÁϺÍÈÝÆ÷ P.8 StabilityÎȶ¨ÐÔ P.8.1 Stability Summary and ConclusionsÎȶ¨ÐÔ×ܽá P.8.2 Postapproval Stability Protocol and Stability CommitmentÉÏÊкóÎȶ¨ÐÔ·½°¸ºÍ³Ðŵ ² °ü×°²ÄÁÏ ² Öü²ØÌõ¼þ ² ÓÐЧÆÚ P.8.3 Stability DataÎȶ¨ÐÔÊý¾Ý ² Ó°ÏìÒòËØÊÔÑ飨¸ßΡ¢¸ßʪ¡¢¹âÕÕ£© ² ¼ÓËÙÊÔÑé ² ³¤ÆÚÊÔÑé |
» ÊÕ¼±¾ÌûµÄÌÔÌûר¼ÍƼö
ÎáÖ®µÀ | ¸ÐÐËȤµÄ |
» ²ÂÄãϲ»¶
ÈçºÎ¸ßЧµÄ²âÁ¿ÏÙ²¡¶¾µÄÁ£¾¶ºÍµçλ
ÒѾÓÐ0È˻ظ´
26ÔÚÖ°É격¡ªÉúÎïÓëÒ½Ò©¡ª¿¹Ìå/ADCÒ©Îï·½Ïò£¬½Õ㻦£¬ÓÐÏîÄ¿£¬¿É´ø×Ê¡£
ÒѾÓÐ1È˻ظ´
Ò©ÎïѧÂÛÎÄÈóÉ«/·ÒëÔõôÊÕ·Ñ?
ÒѾÓÐ148È˻ظ´
288·ÖÇóµ÷¼Á
ÒѾÓÐ0È˻ظ´
Ò»Ö¾Ô¸ËÕÖÝ´óѧ ÉúÎï¼¼ÊõÓ빤³Ì£¨086001£© ³õÊÔ323·Ö£¬Çóµ÷¼Á
ÒѾÓÐ0È˻ظ´
ÈýÄêʵÑéÊÒ¹¤×÷¾Àú£¬Ò»Ö¾Ô¸»ªÖÐũҵ´óѧ΢ÉúÎ×Ü·Ö288Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
070700Çóµ÷¼Á
ÒѾÓÐ1È˻ظ´
Çóµ÷¼Á×Ü·Ö327
ÒѾÓÐ1È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)

³ÕÃÎäìÏæ
ľ³æ (ÖøÃûдÊÖ)
- Ó¦Öú: 16 (СѧÉú)
- ½ð±Ò: 3897.3
- É¢½ð: 2200
- ºì»¨: 107
- ɳ·¢: 8
- Ìû×Ó: 2857
- ÔÚÏß: 1192.5Сʱ
- ³æºÅ: 1120792
- ×¢²á: 2010-10-12
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
4Â¥2013-05-23 19:23:31
YBMCL
½ð³æ (ÕýʽдÊÖ)
- Ó¦Öú: 29 (СѧÉú)
- ½ð±Ò: 1379.9
- ºì»¨: 4
- Ìû×Ó: 348
- ÔÚÏß: 83.6Сʱ
- ³æºÅ: 1312349
- ×¢²á: 2011-06-01
- ÐÔ±ð: GG
- רҵ: Ò©Îﻯѧ
2Â¥2013-05-23 15:41:18
cjtyyh
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 10 (Ó×¶ùÔ°)
- ½ð±Ò: 145.3
- É¢½ð: 300
- ºì»¨: 1
- Ìû×Ó: 293
- ÔÚÏß: 317.1Сʱ
- ³æºÅ: 594839
- ×¢²á: 2008-09-07
- ÐÔ±ð: GG
- רҵ: ÉúÎï¼¼ÊõÒ©Îï
3Â¥2013-05-23 16:19:31
triassic
ͳæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 256.1
- Ìû×Ó: 35
- ÔÚÏß: 15Сʱ
- ³æºÅ: 2544844
- ×¢²á: 2013-07-14
- רҵ: ÉúÎïÎïÀí»¯Ñ§
5Â¥2013-07-14 14:49:56













»Ø¸´´ËÂ¥


